港股异动丨李氏大药厂(0950.HK)升近6% 近日股价走出反转行情
格隆汇9月11日丨李氏大药厂(00950.HK)近期股价攀升上涨,几乎收复此前跌幅。现涨5.8%,报4.56港元,暂成交282.3万港元,最新总市值27亿港元。日前,公司获供应商给予第一的品评,标志着该集团在研发新药以应对医疗需求缺口方面的创新领先地位及承诺皆获得认可。9月初,股价被低估,公司拟回购不超3000万股。回购股份计划亦反映董事会对公司目前业务发展和前景有信心。此前公司中期收入同比增长7.01%至6.08亿港元。有机构称,公司主业扎实效率提升,研发致利润承压仍支撑长期价值。值得一提的是,此次财报公司毛利率继续保持稳定,公司经营效率亦得到不断提升,核心细节数据持续向好,进一步佐证了公司基本面的健康。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.